Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's top five pharma companies - excluding Green Cross and Daewoong Pharmaceutical - posted sluggish sales in the third quarter, most of them still finding ways to cope with the government's tightening grip on their business practices

You may also be interested in...



Korean Pharma Earnings Roundup: Companies Struggled In First Quarter Because of April Price Cuts And Tightened Regulatory Grip On Rebates

As widely expected, top Korean companies were badly hit during the first quarter by April price cuts and a continuing government crackdown on rebates.

Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing

SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011

Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing

SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel